CAMBRIDGE, England and WALTHAM, Mass, May 17, 2023
/PRNewswire/ -- Abcam plc (Nasdaq: ABCM), a global leader in
the supply of life science research tools, announces the voting
results from the Annual General Meeting (the "AGM") held
today. A total of 196,862,506 shares representing 85.7% of
Abcam's issued and outstanding voting capital (including withheld)
were voted in connection with the meeting.
The votes were as follows:
|
Resolution
|
In
Favour
|
Against
|
Withheld
|
|
1.
|
To receive and adopt
the Directors' Report and the financial statements for the period
31 December 2022, together with the Independent Auditor's
Report.
|
180,306,403
99.94%
|
99,238
0.06%
|
16,56,865
8.36%
|
|
2.
|
To approve the Annual
Report on Remuneration for the for the period 31 December 2022, as
set out on pages 49 to 59 of the Annual Report and
Accounts.
|
174,040,019
95.40%
|
8,387,468
4.60%
|
14,435,019
7.33%
|
|
3.
|
To re-appoint
PricewaterhouseCoopers LLP as auditor of the Company to hold office
until the conclusion of the next general meeting at which accounts
are laid before the Company.
|
179,459,110
99.19%
|
1,467,634
0.81%
|
15,935,762
8.09%
|
|
4.
|
To authorise the Audit
and Risk Committee to fix the remuneration of the
auditor.
|
180,876,749
99.97%
|
47,249
0.03%
|
15,938,508
8.10%
|
|
5.
|
To re-elect Peter Allen
as a Director.
|
171,602,332
96.27%
|
6,657,956
3.73%
|
18,602,218
9.45%
|
|
6.
|
To re-elect Alan Hirzel
as a Director.
|
180,868,452
99.99%
|
15,522
0.01%
|
15,978,532
8.12%
|
|
7.
|
To re-elect Michael
Baldock as a Director.
|
173,249,012
95.02%
|
9,075,983
4.98%
|
14,537,511
7.38%
|
|
8.
|
To re-elect Mara
Aspinall as a Director.
|
159,959,959
88.46%
|
20,861,003
11.54%
|
16,041,544
8.15%
|
|
9.
|
To re-elect Giles Kerr
as a Director.
|
161,230,904
89.17%
|
19,590,466
10.83%
|
16,041,136
8.15%
|
|
10.
|
To re-elect Mark Capone
as a Director.
|
180,683,452
99.92%
|
137,918
0.08%
|
16,041,136
8.15%
|
|
11.
|
To re-elect Sally W
Crawford as a Director.
|
179,114,658
99.06%
|
1,706,304
0.94%
|
16,041,544
8.15%
|
|
12.
|
To re-elect Bessie Lee
as a Director.
|
180,674,287
99.92%
|
147,533
0.08%
|
16,040,686
8.15%
|
|
13.
|
To elect Luba Greenwood
as a Director.
|
180,796,348
99.99%
|
25,522
0.01%
|
16,040,636
8.15%
|
|
14.
|
To grant the Directors
the authority to issue shares for cash in certain
circumstances.
|
176,033,135
97.33%
|
4,826,779
2.67%
|
16,002,592
8.13%
|
|
15.
|
To grant the Directors
the authority to disapply pre-emption rights in certain
circumstances.
|
176,443,735
97.56%
|
4,415,332
2.44%
|
16,003,439
8.13%
|
|
16.
|
To grant the Directors
the authority to disapply pre-emption rights for additional equity
securities for the purposes of financing or refinancing a
transaction.
|
167,774,655
92.77%
|
13,083,811
7.23%
|
16,004,040
8.13%
|
|
17.
|
To adopt amended
articles of association of the Company.
|
180,863,563
99.99%
|
18,456
0.01%
|
15,980,487
8.12%
|
|
18.
|
To approve and
authorise forms of share repurchase contract and
counterparties.
|
128,391,815
71.52%
|
51,119,075
28.48%
|
17,351,616
8.81%
|
The issued share capital ("ISC") as of the date of the meeting
was 229,723,147 Ordinary Shares.
The percentage of voting shares in favour and against is the
percentage of shares voted and exclude shares on which votes were
withheld.
For further information, please contact:
|
Abcam
|
|
|
|
Marc Perkins, Company
Secretary
Tommy Thomas
|
+ 44 1223 696
000
+1
617-577-4205
|
tommy.thomas@abcam.com
|
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
antibodies, assays and other research tools to address important
targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health.
Abcam's worldwide customer base of approximately 750,000 life
science researchers uses Abcam's antibodies, reagents, biomarkers
and assays. By actively listening to and collaborating with these
researchers, the Company continuously advances its portfolio to
address their needs. A transparent programme of customer reviews
and datasheets, combined with an industry-leading validation
initiative, gives researchers increased confidence in their
results.
Founded in 1998 and headquartered in Cambridge, UK, the Company has served
customers in more than 130 countries. Abcam's American Depositary
Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq: ABCM).
For more information, please visit corporate.abcam.com.
View original
content:https://www.prnewswire.com/news-releases/abcam-plc-result-of-annual-general-meeting-301827323.html
SOURCE Abcam plc